作者: Nanette K. Wenger , Bernard Chaitman , George W. Vetrovec
DOI: 10.1016/J.AMJCARD.2006.07.052
关键词: Ranolazine 、 Randomized controlled trial 、 Atenolol 、 Incidence (epidemiology) 、 Percutaneous coronary intervention 、 Myocardial infarction 、 Medicine 、 Cardiology 、 Internal medicine 、 Angina 、 Chronic angina
摘要: More women than men with myocardial infarction have previous stable angina pectoris. Women also an increased incidence of after percutaneous coronary intervention and artery bypass grafting. Data from 1,737 patients pectoris in 4 international trials (Monotherapy Assessment Ranolazine In Stable Angina [MARISA], Combination [CARISA], Versus Atenolol Comparison Chronic [RAN080], Efficacy [ERICA]) were used to compare efficacy safety ranolazine therapy for men. MARISA, CARISA, RAN080 included exercise testing; RAN080, ERICA assessed frequency nitroglycerin consumption; quality-of-life assessment using the Seattle Questionnaire. extended-release formulation ranolazine; immediate release. All studies showed overall ranolazine. subgroup analyses, less improvement testing. However, similar improvements noted consumption, ERICA, dimension conclusion, explanations gender treatment differences parameters but comparable effects on decrease use are uncertain, may include patient demographics, reasons stopping exercise, type protocol used.